Profile data is unavailable for this security.
About the company
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
- Revenue in USD (TTM)40.33bn
- Net income in USD5.63bn
- Incorporated1900
- Employees114.00k
- LocationAbbott Laboratories100 Abbott Park Road, Abbot ParkABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com
Mergers & acquisitions
Acquired company | ABT:NYQ since announced | Transaction value |
---|---|---|
Bigfoot Biomedical Inc | 1.07% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DexCom Inc | 3.80bn | 639.30m | 49.95bn | 9.60k | 82.78 | 22.14 | 59.73 | 13.14 | 1.52 | 1.52 | 8.99 | 5.67 | 0.6337 | 2.93 | 4.71 | 396,020.80 | 10.66 | 8.30 | 14.97 | 10.50 | 63.25 | 65.90 | 16.82 | 14.14 | 2.53 | -- | 0.526 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
Edwards Lifesciences Corp | 6.14bn | 1.41bn | 52.70bn | 19.80k | 37.59 | 7.40 | 33.83 | 8.58 | 2.33 | 2.33 | 10.11 | 11.82 | 0.6682 | 1.35 | 8.00 | 310,272.70 | 15.34 | 16.63 | 17.58 | 19.12 | 76.63 | 76.71 | 22.95 | 24.84 | 2.67 | -- | 0.0767 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
Becton Dickinson and Co | 19.72bn | 1.36bn | 66.57bn | 73.00k | 49.03 | 2.61 | 18.22 | 3.38 | 4.70 | 4.54 | 67.74 | 88.32 | 0.3633 | 3.37 | 7.93 | 270,082.20 | 2.54 | 2.37 | 2.94 | 2.70 | 41.25 | 45.78 | 6.99 | 6.95 | 0.9705 | 6.91 | 0.4126 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
Medtronic PLC | 32.36bn | 3.68bn | 108.06bn | 95.00k | 29.45 | 2.13 | 17.02 | 3.34 | 2.76 | 2.76 | 24.34 | 38.29 | 0.3578 | 2.11 | 5.34 | -- | 4.09 | 4.57 | 4.61 | 5.14 | 65.82 | 66.82 | 11.44 | 13.49 | 1.55 | 17.09 | 0.3317 | 80.25 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
Boston Scientific Corporation | 14.71bn | 1.77bn | 109.35bn | 48.00k | 62.10 | 5.49 | 36.71 | 7.44 | 1.20 | 1.20 | 9.99 | 13.56 | 0.4229 | 1.95 | 6.72 | 306,395.80 | 5.09 | 2.50 | 5.90 | 2.91 | 69.46 | 68.84 | 12.05 | 6.47 | 1.14 | 5.43 | 0.3449 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
Stryker Corp | 20.96bn | 3.36bn | 125.76bn | 52.00k | 37.73 | 6.56 | 28.63 | 6.00 | 8.75 | 8.75 | 54.57 | 50.33 | 0.55 | 1.61 | 6.27 | 403,134.60 | 8.82 | 6.60 | 10.60 | 7.84 | 64.01 | 63.99 | 16.03 | 13.13 | 0.9872 | -- | 0.4016 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
Intuitive Surgical, Inc. | 7.32bn | 1.99bn | 141.31bn | 13.68k | 71.89 | 10.12 | 57.06 | 19.31 | 5.54 | 5.54 | 20.41 | 39.36 | 0.5068 | 2.19 | 7.13 | 535,134.60 | 13.88 | 12.42 | 15.39 | 13.83 | 66.43 | 67.60 | 27.38 | 26.31 | 4.61 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
Abbott Laboratories | 40.33bn | 5.63bn | 181.32bn | 114.00k | 32.37 | 4.67 | 20.44 | 4.50 | 3.22 | 3.22 | 23.06 | 22.31 | 0.5514 | 2.67 | 6.39 | 353,736.80 | 7.70 | 7.72 | 9.60 | 9.39 | 55.25 | 56.73 | 13.96 | 14.39 | 1.11 | 22.29 | 0.272 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
Thermo Fisher Scientific Inc | 42.49bn | 6.03bn | 223.32bn | 122.00k | 37.53 | 4.91 | 23.79 | 5.26 | 15.59 | 15.59 | 109.80 | 119.24 | 0.4432 | 4.69 | 4.56 | 348,295.10 | 6.26 | 7.79 | 7.43 | 9.11 | 40.40 | 44.94 | 14.13 | 16.76 | 1.33 | 17.55 | 0.4384 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 157.88m | 9.10% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 86.49m | 4.99% |
Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 83.98m | 4.84% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 74.74m | 4.31% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 70.18m | 4.04% |
Geode Capital Management LLCas of 31 Mar 2024 | 33.73m | 1.94% |
Wellington Management Co. LLPas of 31 Mar 2024 | 28.26m | 1.63% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 19.66m | 1.13% |
Norges Bank Investment Managementas of 31 Dec 2023 | 19.22m | 1.11% |
Polen Capital Management LLCas of 31 Mar 2024 | 16.14m | 0.93% |